Not financial advice. Always do your own research.
IGC Pharma — Analyst Ratings & Price Targets
Coverage is limited but fully bullish. Only 2 Wall Street analysts actively cover $IGC, and both carry Buy ratings.
Ascendiant Capital Markets
Rating: Buy
Price Target: $5.25
Date: April 8, 2026
Alliance Global Partners (AGP)
Rating: Buy
Price Target: $3.00
Date: February 10, 2026
Consensus: 2 Buy | 0 Hold | 0 Sell
Average Price Target: \~$4.13
Target Range: $3.00 – $5.25
Current Price: \~$0.29
Ascendiant raised their target to $5.25 citing clinical progress and upcoming 2026 catalysts, specifically noting they expect "more positive clinical data and progress in 2026 to be strong catalysts for the stock." AGP reiterated their Buy at $3.00 shortly after the company reached 70% CALMA trial enrollment.
The large gap between current price and analyst targets is typical for pre-revenue clinical-stage biotechs — the real test comes when Phase 2 topline data drops, expected after enrollment completes mid-2026.